Durametrix LLC

Establishing the Market-readiness of an in Vivo Technology for Assessing Drug Toxicity-induced Tissue Damage - Project Summary in Drug R&D It Is Critical to Be Able to Understand Toxicity and to Identify and Eliminate Overly Toxic Candidates. However, There Is a Significant Technological Gap for in Vivo Toxicity Testing. to Address This Challenge, We Developed a Novel Imaging-based Approach That Detects Toxicity-induced Tissue Injury in a Minimally Invasive, Whole Body and Dynamic Fashion. the Invention and Development of the Technology Has Had a Substantial Academic Track Record by Our Scientists; and Its Commercialization Is Driven by a Strong Market Need, Technical Expertise and Marketing Know-how. the Goal of the Current Phase I STTR Grant Is Twofold: 1) to Determine the Sensitivity and Specificity of Our Imaging Technology, and 2) to Establish a User-friendly Report System Which Summarizes and Presents the Findings to End Users Who Have a General Drug R&D Background. the Accomplishment of Our Goal Will Enable Us to Launch a Market-ready Service Package With User Accessibility. Overall, This in Vivo Imaging Approach Identifies an Important Marker for Drug Toxicity on a Personalized Basis With an Objective and Quantitative Metric. the Early Detection of Drug Toxicity in Susceptible Tissues Will Help Make Timely Decisions in Drug R&D by Prioritizing Safe and Efficacious Candidates.